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Lipid mediators are produced from the oxidation of polyunsaturated fatty acids through enzymatic and
free radical-mediated reactions. When subject to oxygenation via cyclooxygenases, lipoxygenases, and
cytochrome P450 monooxygenases, polyunsaturated fatty acids give rise to an array of metabolites
including eicosanoids, docosanoids, and octadecanoids. These potent bioactive lipids are involved in
many biochemical and signaling pathways, with inﬂammation being of particular importance. More-
over, because they are produced by more than one pathway and substrate, and are present in a variety
of biological milieus, their analysis is not always possible with conventional assays. Liquid chromato-
graphy coupled to electrospray mass spectrometry offers a versatile and sensitive approach for the
analysis of bioactive lipids, allowing speciﬁc and accurate quantitation of multiple species present in
the same sample. Here we explain the principles of this approach to mediator lipidomics and present
detailed protocols for the assay of enzymatically produced oxygenated metabolites of polyunsaturated
fatty acids that can be tailored to answer biological questions or facilitate assessment of nutritional and
pharmacological interventions.
& 2012 Elsevier Inc. Open access under CC BY license. Introduction
Polyunsaturated fatty acids (PUFAs) are precursors of numer-
ous metabolites endowed with potent bioactivities and involved
in homeostatic and pathophysiological events in the majority of
mammalian cells [1–4]. Although these lipid mediators are,
primarily, products of enzyme-mediated oxygenations, com-
pounds with similar structures can be produced by reactive
oxygen species (ROS)-initiated reactions [5–8]. Enzymatically
derived oxygenated PUFAs originate from three main pathways:
the cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome
P450 (CYP) reactions (Fig. 1). The diversity of PUFA precursors
that can be metabolized in this way is quite broad, resulting in a
large number of mediators whose range of bioactivities continue
to be the focus of current investigations, while new species are
constantly being discovered and their activities remain to be
explored.
One of the most studied families of bioactive lipids are the
eicosanoids. These C20 carboxylic acids are products of arachi-
donic acid (AA; 20:4n6), eicosapentaenoic acid (EPA; 20:5n3),
and dihomo-g-linolenic acid (DGLA; 20:3n6) (Fig. 1). Best
known for their pivotal role in inﬂammation, AA-derived eicosa-
noids are considered to be predominantly proinﬂammatory,
whereas EPA- and DGLA-derived mediators are believed to either
oppose or dampen down this effect, altering the biological milieu5
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CC BY license. to an anti-inﬂammatory one [9]. When metabolized by COX
isoforms (i.e., the constitutive COX-1 or inducible COX-2) and
subject to the prevalence of terminal synthases these C20-PUFA
generate prostaglandins (PGs), prostacyclin, and thromboxanes
(TXs), collectively termed prostanoids [10,11]. Catabolism through
dehydrogenation and reduction results in the formation of meta-
bolites with signiﬁcantly reduced bioactivities (i.e., 15-keto- and
13,14-dihydro-15-keto PGs), representing part of the biological
mechanism that controls tissue levels of bioactive lipids [12].
LOX enzymes insert OH groups in a stereoselective manner
and on a variety of PUFA substrates, including esteriﬁed acyl
species [13–15]. However, LOX activities are commonly deﬁned
by their positional selectivity when they oxygenate AA: in this
way the main mammalian LOX enzymes are deﬁned as 5-LOX,
8-LOX, 12-LOX, and 15-LOX. With the exception of the unique to
mammalian skin 12R-LOX, all other LOX isoforms give hydroxy
fatty acids of the S conﬁguration. LOX isozymes initially produce
unstable hydroperoxides that are then reduced to hydroxy
acids [15]. When subjected to LOX oxygenation PUFAs can
generate an array of mono- and polyhydroxy fatty acids: e.g.,
AA produces hydroxyeicosatetraenoic acids (HETEs), leukotrienes
(LTs), and lipoxins (LXs); EPA generates hydroxyeicosapentaenoic
acids (HEPEs) and E-series resolvins (RvE’s); docosahexaenoic
acid (DHA; 22:6n3) produces docosanoids including hydroxy-
docosahexaenoic acids (HDHAs), maresins, D-series resolvins
(RvD’s), and protectins (PDs); linoleic acid (LA; 18:2n6) forms
octadecanoids such as hydroxyoctadecadienoic acids (HODEs);
DGLA forms hydroxyeicosatrienoic acids (HETrE’s), etc. (Fig. 1).
Interestingly, partially inhibited COX-2 (e.g., acetylated COX-2
Fig. 1. Schematic showing an abridged overview of the main pathways involved in the production of polyunsaturated fatty acid-derived oxygenated mediators. acCOX-2,
acetylated COX-2.
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the OH group at the R conﬁguration, e.g., 15(R)-HETE from AA and
18(R)-HEPE from EPA. These products are important metabolic
precursors of 15-epi-LXA4 and RvE1, respectively, which, in turn,
are generated through sequential LOX reactions via transcellular
metabolism [16,17].
CYP monooxygenases relevant to PUFA metabolism catalyze
epoxygenations and midchain and o-hydroxylations [18–20].
Substrate speciﬁcity and stereoselectivity varies widely between
CYP isoforms, e.g., when using AA as substrate CYP can form
epoxides on every one of the four double bonds of the acyl chain,
forming epoxyeicosatrienoic acid (EET) regioisomers that are
further metabolized by epoxide hydrolases to biologically inactive
dihydroeicosatetraenoic acids (DHET) (Fig. 1). Midchain hydro-
xylations produce a range of LOX-like hydroxy fatty acids (e.g.,
HETE, HEPE) although these mediators are not necessarily of the S
conﬁguration and may not even be enantiomerically pure but
racemic mixtures (reviewed in [5]).
Finally, ROS-mediated reactions can form a range of small lipid
molecules with structures resembling these of enzymatically
produced mediators (Fig. 1). Examples include the isoprostanes,
a family of PG-like regio- and stereoisomeric derivatives formed
through the oxidation of phospholipid esteriﬁed PUFAs, the highly
reactive keto-aldehydes levuglandins and isolevuglandins, as well
as a wide range of monohydroxy fatty acids formed as racemic
mixtures [6,8,21–23].
Given the immense biological importance, increasing number,
and diversity of PUFA-derived oxygenated metabolites, there is a
clear need for a sensitive, selective, and accurate assay system
suitable for the qualitative and quantitative analysis of these lipid
species. Currently, analysis of eicosanoids and other oxygenated
PUFA mediators can be performed using various methodologies:
enzyme-linked immunosorbent assays and radioimmunoassays
are popular but can measure only one metabolite at a time, are
not always selective, can be subject to cross-reactivity, and are
available only for certain lipids [24,25]. Gas chromatography
coupled to mass spectrometry (GC–MS) or tandem mass spectro-
metry (GC–MS/MS) has been successfully applied to eicosanoid
research, although the need to derivatize the lipids to form
volatile species causes limitations including the danger of thermaldecomposition [26–28]. High-pressure liquid chromatography
(HPLC) with ﬂuorescence detection requires derivatization,
whereas HPLC–UV is lacking sensitivity and is applicable only to
a limited number of UV-active mediators [29–31]. However, the
versatility and high separation power of liquid chromatography
(LC—as HPLC or UPLC) when coupled to tandem mass spectro-
metry (LC–MS/MS) have been proven to be an excellent analytical
platform for mediator lipidomic assays with detection limits in
the picogram range [32–37].
Overall, mass spectrometry-based mediator lipidomics offers a
diverse dynamic tool for the simultaneous analysis of multiple
mediators formed by various biochemical routes and all present
in one single sample and has already made its mark on lipid
research: the approach has facilitated the discovery of novel lipid
species while being successfully applied to diverse biological
matrices including plasma, brain, liver, pancreas, cutaneous
blister ﬂuid, myometrial tissue, spinal ﬂuid, breath condensate,
cell culture media, solid tumors, urine, etc. [33–35,38–47]. In this
article we describe detailed experimental protocols for the study
of enzymatically produced oxygenated metabolites of PUFAs
including their extraction from various biological materials,
quantitation, and elucidation of chirality. These protocols can be
tailored to answer targeted or untargeted research questions,
investigate the origin of species of interest, and assess effective-
ness of nutritional and therapeutic interventions.Principles
Mass spectrometry measures the mass-to charge (m/z) ratio of
ionized molecules. Further fragmentation of molecular ion species
generates product ions that provide structural information for the
compound of interest and can inform the development of sensi-
tive quantitative assays. Electrospray ionization (ESI) is a low-
energy (soft) ionization technique applicable to the qualitative
and quantitative analysis of lipid species [48,49]. Although ESI
generates both positively and negatively ionized species, most
applications relevant to oxygenated PUFA mediators are in the
negative-ion mode (ES), in which they form [M-H] carboxylate
ion species in high abundance [50] (Fig. 2).
Fig. 2. ESI–MS spectra for the AA-derived mediators PGE2, 12-HETE, LXA4, and 11(12)-EET, the EPA-derived 18-HEPE and RvE1, and the DHA-derived 17-HDHA and RvD1.
K.A. Massey, A. Nicolaou / Free Radical Biology and Medicine 59 (2013) 45–55 47Tandem mass spectrometry involves multiple rounds of mass
spectrometry in which one mass analyzer produces compound-
speciﬁc fragment ions that can then be selected and further
fragmented, with the resulting product ions studied througha second mass analyzer. This setting allows a number of experi-
mental routines such as the widely used multiple-reaction mon-
itoring (MRM) mode. In a typical MRM experiment the ion of
interest is isolated in the ﬁrst mass analyzer (quadrupole
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argon, and the product ions are then scanned and selected by a
second analyzer (e.g., a second quadrupole) and related back to
their precursor ion. In this way an MRM transition monitors the
formation of compound-speciﬁc fragments giving a very selective
and highly sensitive assay system, with much reduced back-
ground noise, and is immensely useful for quantitative
approaches [51].
Oxygenated PUFA mediators are predominantly hydroxylated
unsaturated carboxylic acids that are typically separated by
polarity using, mostly, C18 reverse-phase columns and acidiﬁed
methanol or acetonitrile-based mobile phase systems [33,34].
One of the advantages of ESI is that it can be readily coupled to
HPLC, offering a great advantage for the development of LC/ESI–
MS/MS assays. MRM assays allow the simultaneous detection of
multiple lipid species using analyte-speciﬁc information deduced
from their MS/MS fragmentation patterns. The dwell time and
intrascan delay determine how many such assays can be mon-
itored in each run (typically 20–30 analytes depending on
instrument speciﬁcations) although the MRM protocol can be
segmented during the run to allow for a much larger number of
mediators to be assessed.
Furthermore, LC/ESI–MS/MS allows the analysis of coeluting
compounds that can be monitored via different MRM transitions,
whereas distinction of isobaric species is achieved by chromato-
graphic separation [34]. Although some diastereomers could be
separated by reverse-phase columns, separation of enantiomeric
species requires the use of chiral columns. Amylose or cellulose
stationary phases that can be run with solvents compatible with
ESI offer good sensitivity [52] (Fig. 4). Finally, quantitation is
based on the use of deuterated internal standards and calibration
lines constructed using commercially available or custom-made
synthetic standards.
Although PGs and hydroxy and epoxy fatty acids can be
simultaneously analyzed [36,37], here we present two separate
assays for the COX- and LOX/CYP-derived mediators. We wanted
the method to include series 1, 2, and 3 prostanoids (DGLA, AA,
and EPA products) as well as deactivated 15-keto- and 13,14-
dihydro keto-PG derivatives, so that it could be applied to various
clinical and nutritional studies, including interventions with n3/
n6 PUFAs. We observed that when we combined both protocols
(COX and LOX/CYP) the resulting LC–MS/MS chromatogram was
very crowded, with most mediators eluting during the early part
of the run. Many of these mediators share common fragment ions,
whereas others, such as PGE/PGD, are isobaric species, and there-
fore good chromatographic separation became necessary for
accurate quantitation, especially when analyzing lipids from
various biological matrices. To achieve optimal separation of
isobaric species we used an acetonitrile-based solvent system.
However, hydroxy fatty acids are less polar than prostanoids and
interact more strongly with a C18 column, leading to peak broad-
ening; hence a more polar solvent such as methanol was required
to give sharper peaks and improve resolution [30]. Resolution of
hydroxy fatty acids was further improved when a core shell (pore
size 2.6 mm) column was employed; however, this type of column
did not improve the chromatography of prostanoids.Materials
Solid-phase extraction cartridges STRATA SPE cartridges,
C18-E (500 mg, 6 ml; Cat. No. 8B-S001-HCH), amber glass vials
with screw cap (2.0 ml; Cat. No. ARO-3811), conical glass
inserts (100 ml; Cat. No. ARO-4520), open-top screw caps (Cat.
No. ARO-8897), and PTFE septa (8-mm diameter, 0.010 in.;
Cat. No. ARO-6817) were from Phenomenex (Macclesﬁeld, UK).Ten-microliter ﬁxed-needle gas-tight glass syringe (Cat. No.
SZR-830-190R), 50-ml ﬁxed-needle gas-tight glass syringe
(Cat. No. SZR-830-210X), 250-ml ﬁxed-needle gas-tight glass
syringe (Cat. No. SZR-830-270T), pH indicator paper sticks, non-
bleeding, supplied with color comparison chart pH 1.7 to 3.8
(856 mm; Cat. No. FB33007), borosilicate glass round-bottomed
screw-neck tubes (16100 mm; Cat. No. TKV-173-020E) with
screw caps (PTFE liner; Cat. No. TKV-178-020U), glass Pasteur
pipettes, and all other lab glassware were from Fisher Scientiﬁc
(Loughborough, UK). Plain glass wide-neck vials, capped (10 ml;
Cat. No. 116105), were from Laboratory Sales Ltd (Rochdale, UK).
Nitrogen (oxygen-free) (Cat. No. UN1066) was from BOC (Man-
chester, UK). Glacial acetic acid (ReagentPlus; Cat. No. A6283),
hydrochloric acid (HCl; ACS reagent; Cat. No. 320331), and
sodium hydroxide (NaOH; ACS reagent; Cat. No. 221465) were
from Sigma–Aldrich Co. Ltd (Dorset, UK). Methanol (Cat. No. M/
4056/17), acetonitrile (Cat. No. A/0626/17), ethanol (Cat. No. E/
0665DF/17), hexane (Cat. No. H/0406/17), and methyl formate
(Cat. No. 12682-0025) were all of HPLC-grade and purchased from
Fisher Scientiﬁc. Deionized water was from an ELGA system (18.2
MO-cm purity, Model Ultra Ionic, Part No. PRIPLB0450, High
Wycombe, UK). RC DC protein assay kit II using bovine serum
albumin (BSA) as protein standard (Cat. No. 500-0122) was from
Bio-Rad Laboratories Ltd (Hemel Hempstead, UK). Ninety-six-well
microplates (PS, sterile; Cat. No. 655161) were from Greiner Bio-
One Ltd (Stonehouse, UK).
The following analytical-grade standards were purchased from
Cayman Chemical Co. (Ann Arbor, MI, USA): 15-deoxy-D12,14-PGJ2
(Cat. No. 18570), PGJ2 (Cat. No. 18500), D12-PGJ2 (Cat. No. 18550),
15-keto-PGE2 (Cat. No. 14720), PGE3 (Cat. No. 14990), PGD3
(Cat. No. 12990), PGE2 (Cat. No. 14010), PGD2 (Cat. No. 12010), PGF2a
(Cat. No. 16010), PGE1 (Cat. No. 13010), PGD1 (Cat. No. 12000), PGF1a
(Cat. No. 15010), TXB3 (Cat. No. 19990), TXB2 (Cat. No. 19030), 6-
keto-PGF1a (Cat. No. 15210), 13,14-dihydro-PGF2a (Cat. No. 16660),
13,14-dihydro-PGE1 (Cat. No. 13610), 13,14-dihydro-15-keto-PGE2
(Cat. No. 14650), 13,14-dihydro-15-keto-PGF2a (Cat. No. 16670),
13,14-dihydro-15-keto-PGE1 (Cat. No. 13650), 13,14-dihydro-15-
keto-PGF1a (Cat. No. 15670), PGB2-d4 (Cat. No. 311210), 79-HODE
(Cat. No. 38400), 713-HODE (Cat. No. 38600), 75-HEPE (Cat. No.
32200), 78-HEPE (Cat. No. 32340), 79-HEPE (Cat. No. 32400),
711-HEPE (Cat. No. 32500), 712-HEPE (Cat. No. 32540), 715-HEPE
(Cat. No. 32700), 718-HEPE (Cat. No. 32840), 75-HETE (Cat. No.
34210), 78-HETE (Cat. No. 34340), 79-HETE (Cat. No. 34400),
711-HETE (Cat. No. 34500), 712-HETE (Cat. No. 34550), 715-HETE
(Cat. No. 34700), 710-HDHA (Cat. No. 33400; 713-HDHA (Cat. No.
33500), 714-HDHA (Cat. No. 33550), 717-HDHA (Cat. No. 33650),
720-HDHA (Cat. No. 33750), 15(S)-HETrE (Cat. No. 36720), LTB4 (Cat.
No. 20110), RvD1 (Cat. No. 10012554), 5(S),6(R),15(S)-LXA4 (Cat. No.
90410), 5(S),6(R),15(R)-LXA4 (15-epi-LXA4; Cat. No. 90415), 5-oxo-
ETE (Cat. No. 90415), 75(6)-EET (Cat. No. 50211), 78(9)-EET (Cat.
No. 50351), 711(12)-EET (Cat. No. 50511), 714(15)-EET (Cat. No.
50651), 75,6-DHET (Cat. No. 51211), 78,9-DHET (Cat. No. 51351),
711,12-DHET (Cat. No. 51511), 714,15-DHET (Cat. No. 51651), and
12(S)-HETE-d8 (Cat. No. 334570). LTB5 (Cat. No. BML-LB005-0050)
was from Enzo Life Sciences (Exeter, UK) and RvE1 (Cat. No.
10007848) was from Cayman Europe (Tallinn, Estonia). PD1 was
kindly provided by Dr. C.N. Serhan, Harvard Medical School (Boston,
MA, USA).Instrumentation
Solid tissue samples were homogenized using a Dounce tissue
grinder with pestle (1 ml; Cat. No. FB56687) from Fisher Scientiﬁc
or an Ystral homogenizer X10/25 (10-mm-diameter shaft, set at
speed of 11 kHz) from The Scientiﬁc Instrument Centre Ltd
K.A. Massey, A. Nicolaou / Free Radical Biology and Medicine 59 (2013) 45–55 49(Winchester, UK). Solid-phase extraction (SPE) was performed
using a 12-position vacuummanifold set (Cat. No. AHO-6023) and
the solvents were removed using an SPE 12-position drying
attachment with nitrogen supply (Cat. No. AHO-6050), all from
Phenomenex. The analysis of lipid mediators was performed
using the following HPLC columns: C18 Luna (1502.0 mm,
5 mm, 100-A˚ particle size; Cat. No. 00F-4252-B0), C18 Kinetex
(1002.1 mm, 2.6 mm, 100-A˚ particle size; Cat. No. 00D-4462-AN),
and LUX Cellulose-1 (1502.0 mm, 3 mm, 1000-A˚ particle size; Cat.
No. 00F-4458-B0), also from Phenomenex. All columns were ﬁtted
with guard columns ﬁlled with the same material: security guard
cartridges C18 (42-mm i.d., Cat. No. AJO-4286) with security guard
analytical cartridge holder (Cat. No. KJO-4282), KrudKatcher Ultra
inline ﬁlter (0.5-mm depth ﬁlter0.004-in. i.d., Cat. No. AFO-8497),
security guard cartridges LUX cellulose-1 (42.0-mm i.d., Cat. No.
AJO-8402) with security guard analytical cartridge holder (Cat. No.
KJO-4282), also supplied by Phenomenex. LC/ESI–MS/MS analysis
was performed on a HPLC pump (Alliance 2695; Waters, Elstree, UK)
with autosampler (2690; Waters) coupled to a triple-quadrupole
mass spectrometer with ESI probe (Quattro Ultima; Waters). Instru-
ment handling and data management were done through MassLynx
version 4.0 (Waters). Ninety-six-well microplates were read using a
Labsystems Multiskan RC microplate reader version 6.0 (650 nm, Cat.
No. 1506250) operated using Gemini 4.0 software (Product No.
5197051; Labsystems Oy, Helsinki, Finland). A Fisions Whirlimixer
(Model WM/250/F; Fisions Science Apparatus, Loughborough, UK)
and a refrigerated bench-top centrifuge (Model RT6000B; Sorvall, UK)
were also used.Protocol
The main steps and workﬂow of this protocol are shown in
Fig. 3. Overall, solid samples are homogenized in 15% methanol/
water (v/v) and liquid samples are adjusted to 15% methanol
(v/v). After this initial step, the homogenate is spiked with the
appropriate internal standards: PGB2-d4 for the COX-mediator
assay and 12(S)-HETE-d8 for the LOX/CYP and chiral assays.
The samples are then acidiﬁed to pH 3.0 and semipuriﬁed by
SPE. The resulting lipid extract is analyzed by LC/ESI–MS/MS
using the appropriate solvent system and column. Speciﬁc details
are as follows.Fig. 3. Flow chart showing the main steps for the LC/ESI–MS/MS mediator
lipidomic assay.Sample preparation and homogenization
A. Preparation of liquid sample volume o200 ml
This procedure is typically applied to cutaneous blister ﬂuid or
other small-volume liquid samples. Defrost the sample on ice and
in the dark. Note. Do not use a water bath to defrost a sample;
the sample can be warmed by using your hand to the point at which
a small amount of ice remains, thus indicating that the sample
temperature is still close to 0 1C. If required, remove a suitable
aliquot for protein content determination (10–20 ml) and store it
separately. Transfer the defrosted liquid sample into a clean plain
glass wide-neck vial (sample vial) while carefully measuring and
recording the volume. Add 1 ml of ice-cold 15% methanol in water
(v/v) and then wash the storage vial with 21 ml of cold 15%
methanol in water (v/v) to collect any remaining biological
sample. Transfer the washes to the sample vial using a glass
Pasteur pipette; the ﬁnal sample volume should be approximately
3 ml. Add 40 ng each of freshly prepared internal standards PGB2-
d4 and 12(S)-HETE-d8 (40 ml of 1 ng/ml in ethanol). Place the lid on
the sample vial and leave the sample homogenate on ice and in
the dark for 15 min.
B. Preparation of liquid sample volume from 5 ml to 200 ml
This procedure is typically applied to preparation of plasma
samples. Defrost the sample on ice and in the dark but do not use
a water bath to defrost a sample (see Section A). If required,
remove a suitable aliquot for protein content determination and
transfer the liquid into a clean plain glass wide-neck vial (sample
vial) while carefully measuring and recording the volume. Add an
appropriate volume of ice-cold water to bring the solution to a
ﬁnal volume of 4 ml. Then add 700 ml of ice-cold methanol to
bring the solution to 15% methanol (v/v). For sample volumes that
are over 2 ml it is advisable to add ice-cold water up to a ﬁnal
volume of 6 ml (maximum SPE capacity) and adjust the volume of
methanol accordingly. In all cases, add 40 ng of freshly prepared
internal standards and continue with the protocol described in
Section A.
C. Preparation of cell culture medium from 10 to 5 ml
Defrost the sample on ice and in the dark but do not use a
water bath (see comments in Section A). Add an appropriate
volume of ice-cold methanol directly to the sample while in its
original container to bring it up to 15% methanol (v/v): i.e., for a
10-ml sample a volume of 1.77 ml ice-cold methanol would be
needed. Then add 40 ng of freshly prepared internal standards
and continue with the protocol described in Section A.
D. Preparation of solid tissue sample
Note. For LC/ESI–MS/MS analysis a tissue sample should typically
weigh between 45 and 200 mg. Extracts from samples 4200 mg
can potentially cause noticeable ion-suppression effects and can
contaminate the LC–MS system. Therefore for tissue samples larger
than 200 mg, it is necessary to cut an appropriately sized section
before extraction. For ‘‘soft’’ tissues (e.g., brain) place the frozen
tissue directly into the Dounce tissue grinder and add 500 ml of
ice-cold methanol. Keeping the tissue grinder on ice, break up
the tissue using the pestle until fully homogenized. If required,
remove an aliquot of the suspension for protein content analysis.
Then, transfer the homogenate into a clean plain glass wide-
neck vial (sample vial), using a glass Pasteur pipette. Wash the
tissue grinder and pestle with 2100 ml of ice-cold methanol
and transfer the washes into the sample vial always using a
glass Pasteur pipette. Add 4 ml of ice-cold water to the sample
vial to bring the homogenate to 15% methanol in water (v/v).
Then add 40 ng of freshly prepared internal standards and
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wash the tissue grinder and pestle with analytical-grade water and
ethanol in between samples to prevent cross-contamination.
When dealing with ‘‘tough’’ tissues (e.g., muscle, skin sections)
place the frozen tissue directly into a clean plain glass wide-neck
vial (sample vial) containing 4 ml of ice-cold 15% methanol (v/v)
in water. Homogenize the tissue using the Ystral homogenizer
X10/25 in 415-s bursts always keeping the solution on ice in
between. If required, remove an aliquot of the suspension for
protein content analysis. Then add 40 ng of freshly prepared
internal standards and continue with the protocol described in
Section A. Note. Carefully wash the blade homogenizer with
analytical-grade water and ethanol in between samples to prevent
cross-contamination.Solid-phase extraction
After incubating the homogenate on ice, centrifuge it at 4 1C,
5000 rpm, for 10 min to remove any precipitated proteins. Note. If
necessary, retain the resulting pellet for protein content determina-
tion and store separately. Transfer the clear supernatant to a clean
plain glass wide-neck vial. Acidify each supernatant to pH 3 using
20–30 drops of 0.1 M HCl (0.1 M HCl: 850 ml concentrated HCl in
100 ml water); this should be sufﬁcient for small-volume liquid
and solid samples. For plasma samples and cell culture media use
1 M HCl (20–30 drops should be sufﬁcient to bring the sample pH
to 3.0). Note. This step is necessary to fully protonate the lipid
mediator species, allowing them to be retained on the C18 SPE
cartridge. However, care must be taken to acidify the samples just
before loading them to the preconditioned SPE cartridges.
Before acidifying the samples, attach the required number of
SPE cartridges to the vacuummanifold. Place a waste bucket in the
manifold to collect and discard the washes. Note. Wash volumes
used in SPE are determined by the mass of the sorbent bed, typically
1ml of solvent is needed per 100mg of bed mass. However, when
extracting biological material for LC/ESI–MS/MS analysis it is vital to
remove all weakly bound impurities from the sorbent bed. If this is not
done effectively, impurities in the ﬁnal lipid mediator extract may
cause ion-suppression effects, leading to a loss in mass spectrometer
sensitivity (see Caveats). Therefore, larger wash volumes are used
(4 5ml on 500mg sorbent bed) to ensure that the extract is as pure
as possible before analysis. Activate the appropriate number of
cartridges by washing them with 20 ml of methanol followed by
20 of ml water. At the end of this step, close the taps to stop the
ﬂow. Note. Do not allow the sorbent bed to run dry at any point
during either the activation or the running of SPE.
Transfer one of the acidiﬁed ice-cold samples onto one of the
activated cartridges using a glass Pasteur pipette. Open the tap
and allow the liquid to pass through in a drop-wise manner.
Apply vacuum if necessary. However, do not allow the ﬂow rate to
become too fast as this will reduce the efﬁciency at which the
lipid mediator species will be retained onto the cartridge. When
all the sample has passed through the SPE and you can see only a
few drops left at the top of the cartridge, close the tap to stop the
sample from running through the SPE. Repeat this step for all the
acidiﬁed samples. Once the samples have been loaded, wash
the cartridges with 20 ml 15% (v/v) methanol in water, followed
by 20 ml water to remove excess salts and other water-soluble
impurities. Then wash with 10 ml hexane to remove any water.
Stop the vacuum and replace the waste container with borosili-
cate glass round-bottomed screw-neck tubes to collect the lipid
extract; these vials should be placed in the manifold collection
rack. Then wash the SPE with 12 ml methyl formate to collect the
lipids. These extracts are then dried under nitrogen and in the
dark (to prevent photodegradation) until completely dry.Lipid extract reconstitution and storage
When planning to analyze lipid mediators using either the
COX or the LOX/CYP assay described here, reconstitute the lipid
extract in 100 ml ethanol/water (70/30; v/v). Note. A small amount
of water is added to the sample solvent to reduce column sensitivity
to ethanol, which can have an effect on peak resolution. For example,
injection of 100% ethanol on the Kinetex C18 column will produce
broad, split peaks at the start of the assay. However, when planning
to use the chiral assay, you should reconstitute the samples in
100 ml ethanol. Note. Using an aqueous solution with the Cellulose-1
column used for the chiral assay can result in longer analyte
retention times. Transfer the lipid extract using a gas-tight glass
syringe into a clean glass insert within an amber glass vial and
tightly seal. The lipid extracts can be stored frozen at 20 1C for
1 week although it is advisable to run them as soon as possible
after extraction.
Preparation of lipid mediator standards
Note. All lipid solutions and extracts should be prepared and
handled using ﬁxed-needle gas-tight glass syringes. Prepare working
standard solutions of 10 ng/ml in ethanol, for every individual
lipid standard. Mix appropriate volumes of each one of these
working solutions to prepare 200 ml of a mixed standard solution
at a ﬁnal concentration of 400 pg/ml per sample, in ethanol.
The composition of this mixed standard will depend on the assays
planned. Note. 15-Epi-LXA4 does not ionize as efﬁciently as LXA4 and
as a result it gives a much lower signal during MRM analysis.
Therefore, to have a good signal for 15-epi-LXA4 we found it
necessary to use a higher concentration of this mediator in the mixed
standard. This is particularly important when planning to compare
the prevalence of 15-epi-LXA4 and LXA4 (e.g., chiral analysis). We are
suggesting a ﬁnal concentration of 4000 pg/ml for 15-epi-LXA4. For
the internal standards, transfer 100 ml of PGB2-d4 (10 ng/ml) into a
glass amber vial and add 900 ml of ethanol to prepare a 1-ml
solution of 1 ng/ml. Repeat this step for 12(S)-HETE-d8 and
prepare also a solution of 1 ng/ml.
To prepare solutions for calibration lines, transfer the appro-
priate volume (see below) of the mixed standard solution
(400 pg/ml) into a clean glass insert vial. Add to it 40 ng of each
internal standard (40 ml of 1 ng/ml solution of PGB2-d4 and/or
12(S)-HETE-d8) and evaporate the solvent to dryness under
nitrogen. When dry, reconstitute the lipid residue with 100 ml of
the appropriate solvent, as follows: use ethanol/water (70/30; v/
v) when planning to run the COX or the LOX/CYP assay; use 100%
ethanol when planning to run the chiral assay. Repeat this process
using various volumes of the mixed calibration standards to
achieve the following concentrations: (a) COX assay, 100, 50, 20,
10, and 2 pg/ml; (b) LOX/CYP assay, 100, 50, 20, 10, and 4 pg/ml;
and (c) chiral assay, 160, 100, 50, 20, and 10 pg/ml.
LC/ESI–MS/MS analysis of prostanoids
Optimal MS parameters should be determined for each indi-
vidual lipid mediator by direct infusion and using a working
standard solution of 10 ng/ml. MS analysis is conducted in
electrospray negative mode. Typical MS/MS parameters for the
Quattro Ultima are capillary voltage 4000 V, cone voltage 35 V,
dwell time 0.2 s, source temperature 100 1C, desolvation tem-
perature 400 1C, ﬁrst and second analyzer (Q1 and Q2) resolution
14.0, and ion energy Q1 and Q2 1.5. The collision energy required
for fragmentation of the individual lipid mediators needs to be
experimentally established; the settings used for this protocol are
shown in Table 1.
Table 1
Experimental conditions used for the LC/ESI–MS/MS analysis of polyunsaturated
fatty acid-derived prostanoids, hydroxy fatty acids, and various chiral hydroxy
fatty acid species.
Mediator MRM (m/z) CE (eV) RT (min)
(A) Prostanoids
15d-PGJ2 315-271 15 18.71
PGJ2 333-271 15 11.08
D12-PGJ2 333-271 15 11.99
15-Keto-PGE2 349-113 23 6.74
PGE3 349-269 15 4.03
PGD3 349-269 15 4.52
PGE2 351-271 17 4.85
PGD2 351-271 17 5.75
PGF2a 353-193 25 3.95
PGE1 353-317 15 4.93
PGD1 353-317 15 5.50
PGF1a 355-311 25 3.86
TXB3 367-169 15 3.04
TXB2 369-169 17 3.54
6-Keto-PGF1a 369-163 23 2.80
13,14-dh PGF2a 355-311 25 5.18
13,14-dh-15-k-PGE1 353-335 12 8.87
13,14-dh-15-k-PGE2 351-333 12 8.05
13,14-dh-15-k-PGF2a 353-113 28 6.90
13,14-dh-15-k-PGF1a 355-193 32 7.64
PGB2-d4 337-179 20 11.99
(B) Chiral hydroxy fatty acid species
15-Epi-LXA4 351-115 20 10.97
LXA4 351-115 20 12.22
RvD1 375-141 15 13.43
RvE1 349-195 17 6.55
18(R)-HEPE 317-133 20 26.80
18(S)-HEPE 317-133 20 29.43
15(R)-HETE 319-175 18 45.45
15(S)-HETE 319-175 18 47.89
17(R)-HDHA 343-201 15 54.77
17(S)-HDHA 343-201 15 59.18
12(R)-HETE 319-179 17 51.68
12(S)-HETE 319-179 17 53.06
12(S)-HETE-d8 327-184 17 51.60
(C) Hydroxy fatty acids
79-HODE 295-171 25 15.00
713-HODE 295-195 25 14.82
75-HEPE 317-115 20 13.04
78-HEPE 317-155 18 11.76
79-HEPE 317-149 20 12.15
711-HEPE 317-167 20 11.56
712-HEPE 317-179 17 11.85
715-HEPE 317-175 18 11.37
718-HEPE 317-133 25 10.89
75-HETE 319-115 20 19.38
78-HETE 319-155 20 17.50
79-HETE 319-123 20 19.02
711-HETE 319-167 20 16.70
712-HETE 319-179 17 17.33
715-HETE 319-175 18 15.72
710-HDHA 343-153 17 17.33
713-HDHA 343-193 17 16.88
714-HDHA 343-161 20 17.33
717-HDHA 343-201 15 16.25
720-HDHA 343-241 20 15.45
15(S)-HETrE 321-221 15 19.47
LTB4 335-195 17 8.39
LTB5 333-195 20 6.43
PD1 359-206 15 5.50
RvD1 375-141 15 4.16
RvE1 349-195 17 1.93
LXA4 351-115 20 4.10
5-Oxo-ETE 317-203 30 20.10
12(S)-HETE-d8 327-184 17 14.66
75(6)-EET 319-191 20 23.58
78(9)-EET 319-127 22 22.24
711(12)-EET 319-208 15 21.44
714(15)-EET 319-113 30 19.02
75,6-DHET 337-145 25 13.39
Table 1 (continued )
78,9-DHET 337-127 25 11.78
711,12-DHET 337-167 22 11.03
714,15-DHET 337-207 25 10.22
CE, collision energy; RT, indicative retention time.
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The COX assay is designed to monitor lipid mediators that are
generated from COX metabolism of DGLA, AA, and EPA and their
15-keto- and 13,14-dihydro-15-keto metabolites. A list of med-
iators included in this assay is shown in Table 1A.1. Prepare the following: solvent A, acetonitrile/water/glacial
acetic acid (45/55/0.02; v/v/v), and solvent B, acetonitrile/
water/glacial acetic acid (90/10/0.02; v/v/v). These mobile-
phase solvents can be kept at room temperature for 2 weeks.2. Prepare a seal wash of acetonitrile/water (90/10; v/v) and a
needle wash of acetonitrile/water (70/30; v/v). These solvents
are required to prevent any cross-contamination of the HPLC
and autosampler during the course of the assay. In addition,
prepare the following column wash solvents: methanol/water/
glacial acetic acid (50/48/2; v/v/v) and methanol/water (50/50;
v/v). These solvents are to be used at the end of the experiment
or in between batches of samples to clean the column.3. Filter and degas all solvents before putting them onto the LC
system. Purge the lines.4. Connect the C18 Luna column and set the ﬂow rate to 0.2 ml/
min. Ensure that there are no leaks and wash the system with
solvent A/solvent B (50/50; v/v) for 1 h.5. Check for any background contamination on the MassLynx
Tune page.6. Set up the following gradient on the MassLynx inlet page: 0.0 to
8.0 min, 100% solvent A; 8.1 to 12.0 min, 50% solvent A; 12.1 to
20.0 min, 30% solvent A; 20.1 to 30.0 min, 100% solvent A.7. Load inlet method and allow to equilibrate at 100% solvent A
(initial gradient conditions) for 30 min. Set the sample cham-
ber to 8 1C and injection volume at 10 ml. Check for any
background contamination on the MassLynx Tune page.8. Load the MassLynx MS method that has been programmed to
scan in MRM mode for the analytes of interest.9. Check for background contamination by setting up multiple
blank injections (n¼3) of ethanol/water (70/30; v/v) on the
MassLynx sample list page.10. Check instrument sensitivity and chromatographic resolution
by setting 20 (midrange calibration) and 2 pg/ml (low-range
calibration) standard injections (n¼3) on the MassLynx
sample list page.11. If all instrument and chromatographic conditions are met
begin sample analysis.12. When the assay is complete, wash the column with metha-
nol/water/glacial acetic acid (50/48/2; v/v/v) for 3 h followed
by methanol/water (50/50; v/v) for a further 3 h. After the
column has been washed, remove from the HPLC, replace end
caps, and store.LC–MS/MS analysis of hydroxy and epoxy fatty acids (LOX/CYP assay)
The LOX and CYP assay is designed to monitor lipid mediators
that are generated from the metabolism of LA, AA, EPA, and DHA
by LOX or CYP enzymes. A list of mediators included in this assay
is shown in Table 1B.
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acetic acid (45/55/0.02; v/v/v), and solvent D, methanol/
water/glacial acetic acid (80/20/0.02; v/v/v). The mobile-
phase solvents can be kept at room temperature for 2 weeks.2. Prepare seal wash, needle wash. and column wash solvents as
described above (step 2, COX assay).3. Filter and degas the solvents before putting them onto the LC
system.4. Connect the C18 Kinetex column and set the ﬂow rate to
0.2 ml/min. Ensure that there are no leaks and equilibrate
with solvent C/solvent D (50/50; v/v) for 1 h.5. Check for any background contamination on the MassLynx
Tune page.6. Set up the following gradient on the MassLynx inlet page:
0.0 to 1.0 min, 70% solvent C; 1.1 to 25.0 min, 17% solvent C;
25.1 to 28.0 min, 0% solvent C; 28.1 to 35.0 min, 70% solvent C.7. Load inlet method and allow to equilibrate at solvent
C/solvent D (70/30; v/v) (initial gradient conditions) for
30 min. Set the sample chamber to 8 1C and injection volume
at 10 ml. Check for any background contamination on the
MassLynx Tune page.8. Load the MassLynx MS method that has been programmed to
scan in MRM mode for the analytes of interest.9. Check for background contamination by setting up multiple
blank injections (n¼3) of ethanol/water (70/30; v/v) on the
MassLynx sample list page.10. Check instrument sensitivity and chromatographic resolution
as described for the COX assay (step 10) and begin sample
analysis.11. When the assay is complete, wash and store the column as
described for the COX assay, step 12.Chiral chromatography
This protocol can be applied to various mono- and polyhydroxy
fatty acids. Typical chromatograms showing the AA-derived 712-
HETE, 715-HETE, LXA4 and 15-epi-LXA4, EPA-derived 718-HEPE,12.2210.97 15-epi LXA4
m/z 351 > 115
26.84 29.43
LXA4
m/z 317 > 133
47.8945.47
18(R)-HEPE 18(S)-HEPE
m/z 319 > 17554.77 59.18
15(S)-HETE15(R)-HETE
17(R)-HDHA 17(S)-HDHA
Time (min)
20.00 40.00 60.00
m/z 343 > 201
4. Typical chromatograms showing the chiral separation of the AA-derived
pi-LXA4 and LXA4, EPA-derived 18(R)- and 18(S)-HEPE, the AA-derived 15(R)-
15(S)-HETE, and DHA-derived 17(R)- and 17(S)-HDHA by LC/ESI–MS/MS
erimental conditions as described under Protocol; 15-epi-LXA4, 2.5 ng on
olumn; all other mediators, 250 pg on the column).and DHA-derived 717-HDHA are presented in Fig. 4. Note. The
cellulose column used in this protocol has to be thoroughly condi-
tioned with isopropanol before being used with aqueous mobile
phases suitable for reverse phase-like separation. A short list of some
of the mediators that can be analyzed using this assay is shown in
Table 1C.1. Prepare the following solvents separately: (a) acetonitrile
with 0.001% glacial acetic acid, (b) water with 0.001% glacial
acetic acid, (c) methanol with 0.001% glacial acetic acid. Note.
It is necessary to prepare each solvent separately. The chiral
column is very sensitive to any changes in mobile-phase compo-
sition and, to ensure reproducible retention times, is it advisable
to mix the individual solvent components of the mobile phase via
the inlet method of the HPLC.2. Prepare seal wash, needle wash, and column wash solvents as
previously described (step 2, COX assay).3. Filter and degas each solvent before putting it onto the LC
system.4. Connect the LUX Cellulose-1 column and set the ﬂow rate to
0.2 ml/min. Ensure that there are no leaks and equilibrate
with acetonitrile/water/methanol in 0.02% glacial acetic acid
(39/58/3 v/v/v) for 3 h (see Note for step 1 above).5. Load MassLynx Tune page and check for any background
contamination.6. Load inlet method and set the sample chamber to 8 1C and
injection volume at 5 ml.7. Load the MassLynx MS method that has been programmed to
scan in MRM mode for the analytes of interest.8. Check for background contamination by setting up multiple
blank ethanol injections (n¼3) on the MassLynx sample
list page.9. Check instrument sensitivity and chromatographic resolution
as described for the COX assay (step 10) and begin sample
analysis.10. When the assay is complete, wash and store the column as
described for COX assay (step 12).Protein content determination
For liquid samples remove a protein aliquot (typically 10–20
ml) before adding methanol to the sample. For solid samples
either remove a small aliquot of the homogenate or collect the
protein pellet after centrifuging the sample homogenate. Store
the samples at 20 1C awaiting analysis. The protein pellet
cannot be dissolved in water but it helps to suspend it in 1 M
NaOH (1 ml) (1 M NaOH: 4 g NaOH in 100 ml water) and warm
the solution in a water bath. The assay is carried out using a
96-well microplate format and following the manufacturer’s
instructions using BSA as the protein standard.
Data analysis
Data analysis is carried out using MassLynx version 4.0. Analyte-
related peaks are identiﬁed by the relevant MRM transition and
retention time compared to the standards of the day. All peaks are
integrated and the integrals are recorded in a spreadsheet. Analytes
can be quantiﬁed with accuracy when the signal-to-noise (S/N) ratio
is at least 10; this is deﬁned as the limit of quantitation. When the
S/N is at least 3, the analyte is at the limit of detection (LoD) of the
method [53]. The S/N can be estimated using the operating software
(MassLynx). The limit of detection of lipid mediators varies because of
differences in ionization efﬁciency. For the assays reported here
the LoD ranges as follows: 0.1 to 10 pg/ml for the COX assay, 0.1 to
20 pg/ml for the LOX/CYP assay, and 10 to 20 pg/ml for the chiral
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is 20 and 32 pg/ml, respectively, whereas when using the chiral assay,
the LoD for 12(S)-HETE is 2 ng/ml. Note. Using a chiral stationary phase
has an additional impact on assay sensitivity due to unavoidable ‘‘column
bleed.’’ This in turn produces an ion-suppression effect (see Caveats) with
ESI that affects ionization efﬁciency. As a result the LoD for the chiral
assay is higher (less sensitive) than that of assays using the more stable
C18 stationary phase.Calculations and expected results
Calibration lines are constructed using the least-squares linear
regression method. To determine the concentration of any given
analyte the peak area to internal standard ratio is calculated
and read off the corresponding calibration line as concentration
(pg/ml). The results are then normalized using the sample volume
or the amount of protein or the wet tissue weight and reported as
pg mediator/ml sample or pg lipid mediator/mg protein or pg lipid
mediator/mg tissue, respectively. The assays reported here can be
applied to biological, clinical, and in vitro samples.
Example of results obtained from liquid biological samples
Cutaneous suction blister ﬂuid samples (71744 ml) were
collected from healthy subjects (n¼18) 12 h after blistering and
after 28 day of supplementation with placebo (mineral oil;
2.4 ml) [44]. The concentrations of PGE2 and 12-HETE were
estimated at 0.5970.34 and 15.0970.34 pg/mg protein, respec-
tively. Analysis of plasma samples (7997145 ml) collected from
the same individuals determined that the levels of PGE2 and
12-HETE were 0.2870.11 and 0.0570.03 pg/ml, respectively.
In addition, chiral analysis of the lipid extract obtained from the
cutaneous blister ﬂuid identiﬁed 12(S)-HETE as the dominant
enantiomer, suggesting that this was not a product of oxidation
but enzymatic oxygenation of AA through 12-LOX.
Example of results obtained from solid biological samples
PGE2 and 12-HETE were identiﬁed in the pancreas of FAT-1
transgenic mice (n¼4) at 9.473.82 and 49.5730.2 pg/mg pro-
tein, respectively [39]. The CYP-derived mediator 11(12)-EET has
been identiﬁed in benign endometrial tumor at 165 pg/mg pro-
tein or 16.4 pg/mg tissue (unpublished data).Caveats
A limitation of ESI is the occurrence of ion-suppression (matrix)
effects, which are typically caused by mobile-phase additives
(such as acids and bases) and coeluting impurities from biological
samples [54,55]. Such inﬂuences on analyte ionization efﬁciency
can have an impact on instrument sensitivity. Sample related
matrix effects can be minimized through sample cleanup by SPE. It
is also advisable to use small injection volumes (typically 2–10 ml)
and take appropriate measures during a sample run to keep the
system as clean as possible, i.e., an appropriate needle wash or seal
wash. Interspersing blank injections through the course of the run
is a very useful way to monitor carryover and background
contamination. Also the type and concentration of acid used in
the mobile phase should be carefully selected.
Some other drawbacks may rise from the choice of internal
standards used in the assays. Although 13C-labeled eicosanoids would
have been a better choice, these are not commercially available,
making deuterium-labeled standards the only accessible option.
However, these standards do not have the exact same retentiontimes as the corresponding unlabeled eicosanoids, and their presence
may result in differential suppression or enhancement of ionization
and, consequently, affect the quality of the analytical data [56,57].
The number of deuterium-labeled internal standards can vary
according to the experimental design. Here, we have opted to use
only two, namely PGB2-d4 and 12(S)-HETE-d8, as class-representative
compounds (prostanoids and hydroxy fatty acids). Their recovery was
comparable to that of the analytes of interest and in this way can
compensate for any losses during extraction [33,34]. Whereas the
ionization efﬁciencies of different lipid mediators vary and the two
internal standards cannot account for all changes, quantitation is
based on the use of calibration lines made with synthetic eicosanoid
standards that ionize similar to the lipids of interest. Furthermore, the
calibration lines are run on a daily basis, bracketing the biological
samples and being spiked with the same internal standards used for
the biological samples, addressing some of these concerns.
Systemic eicosanoid production, often used to evaluate various
pathological conditions such as HIV, cancer, and renal disease, can be
assessed through measurement of urinary metabolites (e.g., dinor-
and tetranor-PGs) [58,59]. However, plasma eicosanoids are a better
marker for blood cells and are used as inﬂammatory biomarkers
often associated with the effectiveness of nutritional and other
interventions [44,60]. Nevertheless, it should be noted that because
of the rapid nature of eicosanoid metabolism, plasma mediators may
not be fully representative of total in vivo production.
Finally, it should be pointed out that when collecting human or
animal plasma samples, platelets may become activated and
produce large quantities of 12-HETE. This problem can be mini-
mized if blood is collected directly in containers with antic-
oagulant, but cannot always be avoided.
Caution. Keep all samples and standard solutions on ice
throughout the experiment. Furthermore, lipids are prone to
photodegradation; therefore avoid exposure to direct sunlight.
Ethanol easily evaporates; therefore it is important to keep all
sample extracts and solutions of standards in tightly sealed tinted
vials. For long-term storage (stock solutions of standards) keep
the solutions at 80 1C; for short-term storage (biological
extracts or working solutions of standards) store the samples at
20 1C for no more than 1–2 weeks.
Caution. To avoid cross-contamination of lipid standards and
biological extracts it is essential to rinse out all the glass syringes
thoroughly using ethanol. It also advisable to use syringes
dedicated to handling standards or biological sample extracts.
Caution. When using organic solvents in volumes greater than
10 ml appropriate safety measures should be taken. Methyl
formate, methanol, and hexane are toxic.
Caution. There is a limit to the number of MRM transitions that
can be recorded without compromising the sensitivity of the
assay. Although this number is instrument speciﬁc, it is advisable
to segment the MRM protocol in accordance with the retention
time of mediators of interest.Acknowledgments
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